Investigation Of The Effect Of Steady State Filibuvir On The Pharmacokinetics Of Oral Contraceptives (Levonorgestrel And Ethinyl Estradiol)
Completed
Pfizer
Phase 1
The purpose of this study is to estimate the effect of filibuvir on the pharmacokinetics of
ethinyloestradiol [EE] and levonorgestrel [LN], to assess the safety and tolerability of 600
mg BID of filibuvir in healthy women and to investigate the pharmacokinetics of 600 mg BID of
filibuvir in healthy women.
Filibuvir In Treatment Naive Hepatitis C Virus (HCV) Genotype 1 Subjects
Completed
Pfizer
Phase 2
The primary objective for this study is to determine if the addition of filibuvir to a
standard regimen of peginterferon/ribavirin (pegIFN/RBV) significantly increases the
proportion of subjects who achieve a sustained viral response (SVR) compared to
peginterferon/ribavirin (pegIFN/RBV) therapy alone.
A Study To Investigate Safety And Pharmacokinetics Of A Single Dose Of PF-00868554 (Filibuvir) In Japanese Healthy Adult Volunteers
Completed
Pfizer
Phase 1
A single dose of PF-00868554 (filibuvir) will be safety and tolerable in Japanese healthy
volunteers. The pharmacokinetics in Japanese will be consistent to that available in Western
population.
Drug Interaction Study Of Filibuvir With Methadone Among Subjects On Chronic Methadone Maintenance
Completed
Pfizer
Phase 1
Filibuvir, a CYP3A4 inhibitor is being developed for the treatment of chronic Hepatitis C
infection. Given the likelihood of co administration of filibuvir and methadone, this study
will evaluate the effect of filibuvir on the pharmacokinetics of R/S Methadone.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
